JOYZYME GROUP LIMITED
愉悅集團有限公司

(Incorporated in Cayman Islands with limited liability)
(Stock Code: 8622)

ANNOUNCEMENT MADE PURSUANT TO RULE 17.50A(2) OF THE GEM LISTING RULES

This announcement is made by Joyzyme Group Limited (the "**Company**") pursuant to Rule 17.50A(2) of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the "**GEM Listing Rules**").

The board of directors of Company (the "**Board**") has been informed by Dr. Cheng Faat Ting Gary ("**Dr. Cheng**"), an independent non-executive Director, that pursuant to a press release (the "**Press Release**") issued by the Accounting and Financial Reporting Council (the "**AFRC**") on 10 September 2026, the AFRC has issued public reprimand to, among others, Dr. Cheng and Gary Cheng CPA Limited ("**GCCL**", together with Dr. Cheng are collectively referred to as the "**Auditor**"), a firm of Hong Kong certified public accountants which Dr. Cheng is the managing director and engagement director who acted in the audit of the consolidated financial statements of a Hong Kong listed company (the "**Client**") for the year ended 31 December 2021 (the "**2021 Audit**") for breach of independence requirements and audit deficiencies concerning external confirmation and journal entry testing.

According to the Press Release, the AFRC imposed pecuniary penalties of HK$350,000 on Dr. Cheng. The AFRC found that, concurrently with the 2021 Audit, a consultancy firm within the GCCL's network provided internal control review services to the Client's two major subsidiaries which covered the revenue and receivable cycles. The provision of such dual services is strictly prohibited under the Code of Ethics for Professional Accountants for public interest entity audits. The AFRC also found deficiencies in the Auditor's work in relation to trade receivables and journal entry testing.

The Board has carefully assessed the Press Release and has made enquiries with Dr. Cheng, noting that (i) there is no evidence that there was any act of dishonesty, fraudulence or issue of integrity on Dr. Cheng's part which would affect his suitability as a director of the Company; (ii) the Press Release did not relate to the affairs of the Company and will not have any impact on the Company; (iii) Dr. Cheng had a clean disciplinary record with the AFRC and the Hong Kong Institute of Certified Public Accountants; and (iv) Dr. Cheng's prior and present professional and business experiences continue to be valuable to the Company. The Board, including members of the Nomination Committee of the Company, is therefore of the view that Dr. Cheng remains suitable as an independent non-executive director of the Company.

By Order of the Board
Joyzyme Group Limited
Dr. Zhou Xunyong
Chairman and Executive Director

Hong Kong, 15 September 2026

As at the date of this announcement, the executive Directors are Dr. Zhou Xunyong, Ms. Zhang Yujing, Mr. Zhang As at the date of this announcement, the executive Directors are Dr. Zhou Xunyong, Ms. Zhang Yujing, Mr. Zhang Chunguang and Mr. Poon Lai Yin Michael; the Non-executive Director is Dr. Bu Su; and the Independent Non-executive Directors are Dr. Chow Kwok Fai Joseph, Ms. Wang Yachun and Dr. Cheng Faat Ting Gary.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Company Announcements" page of the Stock Exchange website at www.hkexnews.hk for at least seven days from the date of publication and on the Company's website at www.joyzymebiotech.com.